

## 33998-705 831 ST25.txt SEQUENCE LISTING

`<110>	Scu Gard	n, Norman lly, Audra dell, Luis son, Roger tafsson, Mag	gnus		·							
<120>	120> USE OF LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION											
<130>	30> 33998-705.831											
<140> <141>	10/590,001 2006-08-17											
<150> <151>	PCT/US2004/036952 2004-11-04											
<160>	<160> 2											
<170>	<170> PatentIn version 3.3											
<210> <211> <212> <213>	<211> 2631 <212> DNA											
<400>	1											
		acaacctatt			,		60					
gacaca	ggtt	gtagagatag	agatggctct	ggctgtgcat	tcagcagatt	ctgtagatag	120					
aattaa <sup>.</sup>	tagg	acttggatgg	gattgtggtg	agagaaagtg	aaatgaaaga	taagttctag	180					
tttggaa	agtt	ttaacaactg	aatgtttaaa	ctcaaataga	cacaaaatat	tggaagagtg	240					
gcaggt	ttgg	gaggatgaga	caatcaactg	tttggttgag	ccacgttagg	tttgaaatgt	300					
ctacgg	gatc	ccgtggggag	aggttatatc	agactggagc	accagagaga	ggccaaggct	360					
gatagt	ttag	atgaaaagag	agcatgatat	tttaagccct	gagactggat	aatatcacct	420					
atagaaa	agac	tatatagaga	taagagaggt	ggggaacaag	taaaagctgc	gggacactcc	480					
taaatti	taga	gtcaaattta	gagcagaaaa	tactagcaaa	ggggactgaa	aagcggtggc	540					
caattg	agct	tcaaatgcaa	gtgaaagtgt	gttgtgtgta	catttatcat	ctcatggcac	600					
aggaaaa	aacg	tgatttaagg	agaaggaagc	gatccaatgg	gaagaagaga	tccaatggat	660					
cctcta	tcac	gaagatattg	agataagaac	caatatggat	ttgcacccac	tgcatttgca	720					
gccttga	aggt	cataagcatc	ctcaggaaaa	tgcaccaggt	gctgctggca	agatggaaac	780					
caactt	ctcc	actcctctga	atgaatatga	agaagtgtcc	tatgagtctg	ctggctacac	840					
tgttctg	gcgg	atcctcccat	tggtggtgct	tggggtcacc	tttgtcctcg	gggtcctggg	900					
caatgg	gctt	gtgatctggg	tggctggatt	ccggatgaca	cgcacagtca	ccaccatctg	960					
ttacct	gaac	ctggccctgg	ctgacttttc	tttcacggcc	acattaccat	tcctcattgt	1020					

		33	3998-705 833	l ST25.txt		
ctccatggcc	atgggagaaa				taattcacat	1080
cgtggtggac	atcaacctct	ttggaagtgt	cttcttgatt	ggtttcattg	cactggaccg	1140
ctgcatttgt	gtcctgcatc	cagtctgggc	ccagaaccac	cgcactgtga	gtctggccat	1200
gaaggtgatc	gtcggacctt	ggattcttgc	tctagtcctt	accttgccag	ttttcctctt	1260
tttgactaca	gtaactatta	caaatgggga	cacatcatgt	actttcaact	ttgcatcctg	1320
gggtggcacc	cctgaggaga	ggctgaaggt	ggccattacc	atgctgacag	ccagagggat	1380
tatccggttt	gtcattggct	ttagcttgcc	gatgtccatt	gttgccatct	gctatgggct	1440
cattgcagcc	aagatccaca	aaaagggcat	gattaaatcc	agccgtccct	tacgggtcct	1500
cactgctgtg	gtggcttctt	tcttcatctg	ttggtttccc	tttcaactgg	ttgcccttct	1560
gggcaccgtc	tggctcaaag	agatgttgtt	ctatggcaag	tacaaaatca	ttgacatcct	1620
ggttaaccca	acgagctccc	tggccttctt	caacagctgc	ctcaacccca	tgctttacgt	1680
ctttgtgggc	caagacttcc	gagagagact	gatccactcc	ctgcccacca	gtctggagag	1740
ggccctgtct	gaggactcag	ccccaactaa	tgacacggct	gccaattctg	cttcacctcc	1800
tgcagagact	gagttacagg	caatgtgagg	atggggtcag	ggatattttg	agttctgttc	1860
atcctaccct	aatgccagtt	ccagcttcat	ctacccttga	gtcatattga	ggcattcaag	1920
gatgcacagc	tcaagtattt	attcaggaaa	aatgcttttg	tgtccctgat	ttggggctaa	1980
gaaatagaca	gtcaggctac	taaaatatta	gtgttatttt	ttgttttttg	acttctgcct	2040
ataccctggg	gtaagtggag	ttgggaaata	caagaagaga	aagaccagtg	gggatttgta	2100
agacttagat	gagatagcgc	ataataaggg	gaagacttta	aagtataaag	taaaatgttt	2160
gctgtaggtt	ttttatagct	attaaaaaaa	atcagattat	ggaagttttc	ttctattttt	2220
agtttgctaa	gagttttctg	tttctttttc	ttacatcatg	atgtgacttt	gcattttatc	2280
aaatgcattt	tctacatgta	ttaagatggt	catattattc	ttcttctttt	atgtaaatca	2340
ttataaataa	tgttcattaa	gttctgaatg	ttaaactact	cttgaattcc	tggaataaac	2400
cacacttagt	cctgatgtac	tttaaatatt	tatatctcac	aggagttggt	tagaatttct	2460
gtgtttatgt	ttatatactg	ttatttcact	ttttctacta	tccttgctaa	gttttcatag	2520
aaaataagga	acaaagagaa	acttgtaatg	gtctctgaaa	aggaattgag	aagtaattcc	2580
tctgattctg	ttttctggtg	ttatatcttt	attaaatatt	cagaaaaatt	c	2631

<sup>&</sup>lt;210> <211> <212> <213>

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser Page 2

<sup>2</sup> 351 PRT Human neutrophils and monocytes

<sup>&</sup>lt;400>

15

Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val 20 25 30

Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val Ile 35 40 45

Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys Tyr 50 60

Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro Phe 65 70 75 80

Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp Phe 85 90 95

Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly Ser 100 105 110

Val Phe Leu Ile Gly Phe Ile Ala Leu Asp Arg Cys Ile Cys Val Leu 115 120 125

His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys 130 135 140

Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val 145 150 155 160

Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys 165 170 175

Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys 180 185 190

Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile 195 200 205

Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile 210 220

Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu 225 230 235 240

Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro 245 250 255

33998-705 831 ST25.txt
Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser . 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe 290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser 305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala 325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met 340 350